PDF  | Print |

IMPROVEMENT IN MUCOSAL INTEGRITY AND FUNCTION IN IBD PATIENTS AND REDUCTION IN GI SYMPTOMS IN HIV PATIENTS WITH DIETARY PEPTIDES FROM HYDROLYZED WHITE FISH

Nichols TW, DelRossi J

Center for Nutrition and Digestive Disorders, Hanover, PA, USA

ABSTRACT (Regulatory Peptides. 2002;108(1):31)

Dietary peptides are known to have biological importance beyond their nutritive value as protein, influencing structural, immune, and gastrointestinal functions.  The GI benefit of supplementation with a dietary bioactive peptide supplement prepared from hydrolyzed white fish was studied in two distinct populations in separate trials.  In the first study, 15 IBD patients assessed to have gut mucosal hyperpermeability by a urine test utilizing lactose and mannitol ratios were given either 3g per day of the fish peptide supplement or a control for 6 weeks, followed by a second permeability test and symptom assessment scoring.  Results with the IBD patients taking the supplement showed a trend towards improvement in both intestinal permeability and symptom assessment versus controls.  We then hypothesized that if GI symptoms resulting from current recommended HIV therapy are associated with a similar inflammatory mechanism, these patients would also respond favorably to the peptide supplementation.  Accordingly, a second population of 23 HIV-infected males experiencing GI side effects on highly active antiretroviral therapy (HAART) were given either 3g per day of the fish peptide supplement or a control for 5 months, with symptoms assessed before and after the treatment period.  In the HIV patients, the number of GI symptoms collectively reported as decreased in the supplement group was significantly greater than the number of symptoms collectively reported as decreased in the control group.  These bioactive peptides appear to have a dual function in HIV patients: controlling intestinal permeability as a potential long-term risk factor of HAART and reducing the GI side effects of HAART, which may relate to increased compliance and improved treatment outcome.

1.  INFLAMMATORY BOWEL DISEASE (IBD)

Background/Aims: Inflammatory Bowel Disease (IBD) is a chronic inflammatory condition generally categorized as either ulcerative colitis (UC) or Crohn’s disease, based on established disease criteria and the location of the inflammation.  Recommended medical treatment includes corticosteroid therapy, as well as nutritional interventions, such as elemental peptide diets and micronutrient supplementation.<!--[if !supportFootnotes]-->[1]<!--[endif]-->  Oligomeric (small-chain peptides or hydrolyzed protein) supplementation is preferred over monomeric (free amino acid) or polymeric (whole protein) supplementation based on evidence of increased biological value<!--[if !supportFootnotes]-->[2]<!--[endif]--> and increased nitrogen balance in Crohn’s patients.<!--[if !supportFootnotes]-->[3]<!--[endif]-->  Seacure® is a commercially available hydrolyzed fish protein supplement that provides peptides, as well as omega-3 fatty acids and minerals.

Both UC and Crohn’s are associated with intestinal epithelial hyperpermeability, although the evidence is more established for the latter.<!--[if !supportFootnotes]-->[4]<!--[endif]-->  Successful treatment of Crohn’s with elemental diets is demonstrated by a reduction in intestinal permeability (IP), and normal IP in IBD patients has prognostic implications and may predict well-being.<!--[if !supportFootnotes]-->[5]<!--[endif]--> 

Methods: In a randomized, double-blind, placebo-controlled trial, 15 IBD patients were given either Seacure® (N=7) or barley placebo (N=8), 2x500mg capsules TID, for 6 weeks.  IP was assessed before and after the trial period using lactulose and mannitol probes in urine, testing performed by Great Smokies Diagnostic Laboratories, Asheville, NC.  Successful treatment of IBD is matched by a reduction in lactulose:mannitol ratio.<!--[if !supportFootnotes]-->[6]<!--[endif]-->  Statistical analysis was performed using SAS, paired T-tests.

 

Results:  We did not show a significant change in IP scores among control patients (p=0.41), while Seacure® patients demonstrated a non-significant trend towards improvement in IP scores (p=0.07).  As shown, the percent changes in IP scores, calculated by standardizing starting points for both control and test patients, were 76% improvement in Seacure® patients and 32% improvement in control patients (maintained on standard treatment without supplementation).

 

2.  HIV- HAART THERAPY

Background/Aims: When properly used in HIV management, highly active antiretroviral therapy (HAART) can prevent opportunistic infections (OIs), maintain weight, improve viral counts, delay the progression to AIDS, and extend life.<!--[if !supportFootnotes]-->[7]<!--[endif]-->,<!--[if !supportFootnotes]-->[8]<!--[endif]-->  However, GI complaints, such as diarrhea, affect an estimated 50-70% of HIV patients on HAART.<!--[if !supportFootnotes]-->[9]<!--[endif]-->,<!--[if !supportFootnotes]-->[10]<!--[endif]-->  Such events can limit compliance to HAART, which leads to sub-therapeutic drug levels, viral mutations against HAART agents, and failure to achieve or maintain viral suppression.  The management of GI issues in HIV patients on HAART relates to quality of life and may play a role in compliance with medications and treatment outcome.

An apparent relationship exists between HIV and the health of the GI tract, including intestinal permeability, gut-associated immune function, and oxidative stress,<!--[if !supportFootnotes]-->[11]<!--[endif]--> although the particular inflammatory and functional changes in HIV-related intestinal disease remain unclear.<!--[if !supportFootnotes]-->[12]<!--[endif]-->  Prompted by success with GI symptoms among IBD and irritable bowel syndrome (IBS) patients with the fish peptide supplement Seacure®, we hypothesized that if similar mechanisms are in effect, HIV patients experiencing GI symptoms on HAART might also respond favorably to the fish peptide supplementation.

Methods: The site for the study was a large urban private medical practice with approximately 400 HIV-positive patients.  Thirty-two patients were selected over a two-month period based on the following inclusion criteria:

·         HIV-positive

·         Ability to provide informed consent

·         Ability to adhere to daily supplement regimen

·         Life expectancy of at least 6 months

·         Age greater than 18 years

·         Absence of any OIs

·         Compliance with uninterrupted HAART for at least 6 months

·         Viral load of less than 50 copies/mL and exclusion criteria:

·         Female gender

·         Life expectancy of less than 6 months

·         Opportunistic malignancy requiring systematic chemotherapy within 30 days of study entry

·         The presence of any OIs

·         Concurrent use or prior use of anabolic agents/appetite stimulants/corticosteroids within 30 days of study entry

 

Study design was as follows:

·         Randomized, double-blind, placebo-controlled

·         5 month duration with follow up

·         Treatment: Seacure® (N=18) or barley placebo (N=14), 2 x 500mg capsules TID

·         Outcome-based study design using patient questionnaires and clinician interviews.  The use of questionnaires to evaluate quality of life issues related to HAART and nutritional support has been documented.<!--[if !supportFootnotes]-->[13]<!--[endif]-->

·         Statistical analysis was performed using unpaired, two-tailed T-tests assuming normal distributions and equal variances.  P-value of <0.05 was required for statistical significance.

Results:  Mean age of patients was 43.9 years (30-64).  Five patients in the Seacure® group were lost to follow up, one patient withdrew from the study prior to completion, and one patient died from Hepatitis B two months into the study.  Two patients in the placebo group withdrew prior to completion.  Twenty-three patients completed the study (test N=11, control N=12) and were used for data analysis.  Blood profiles were monitored and remained stable for all patients.

Table 1.  Analysis of study results based on 11 patients in Seacure® group and 12 patients in placebo group at the start of the study.

Symptom

Number of Seacure® patients reporting symptom at baseline

Number of Placebo patients reporting symptom at baseline

Diarrhea

7

7

Nausea

4

4

Constipation

2

2

Bloating

7

6

Fatigue

9

9

MEAN

5.8±2.8

5.6±2.7

Table 2.  Statistical analysis of study results based on 11 patients in Seacure® group and 12 patients in placebo group at the conclusion of the study (5 months).

Symptom

Number of Seacure® patients reporting a decrease in symptom at 5 months

Number of Placebo patients reporting a decrease in symptom at 5 months

Diarrhea

7

2

Nausea

3

1

Constipation

0

0

Bloating

5

1

Fatigue

4

1

MEAN

3.8±2.6*

1.0±0.71

*p=0.0479

As seen in Table 1, there was no difference between the two study groups in the number of patients reporting symptoms at baseline (p=0.911).  At five months, Table 2, the number of symptoms collectively reported as decreased in the Seacure® group was significantly greater than the number of symptoms collectively reported as decreased in the control group (p=0.0479).  Further, all 11 Seacure® patients and two of 12 placebo patients felt better overall.

CONCLUSION

We observed a trend towards improvement in IP and symptoms in IBD patients, as well as a significant decrease in total GI symptoms in HIV-positive males on HAART when supplemented with the fish peptides.  Clinicians must recognize that, to the patient, the GI effects of HAART are a disease unto themselves.  The management of GI issues in HIV treatment may relate not only to quality of life, but also to HAART compliance, and thus, contribute to viral suppression and extend life. Supplementation with these fish peptides may control intestinal permeability as a potential long-term risk factor of HAART and reduce the GI side effects of HAART, which may relate to increased compliance and improved treatment outcome.  Further study is indicated.

Sponsored by Proper Nutrition, Inc., Reading, PA

Call 800-555-8868 for more information

<!--[if !supportEndnotes]-->
<!--[endif]-->

<!--[if !supportFootnotes]--> [1]<!--[endif]--> Bashir S, Lipman TO. Nutrition in gastroenterology and hepatology. Primary Care. 2001;28(3).

<!--[if !supportFootnotes]--> [2]<!--[endif]--> Poullain MG, Cezard JP, Roger L, et al. Effect of whey proteins, their oligopeptide hydrolysates and free amino acid mixtures on growth and nitrogen retention in fed and starved rats. JPEN. 1989;13:382.

<!--[if !supportFootnotes]--> [3]<!--[endif]--> Smith JL, Areaga C, Heymsfield SB. Increased ureagenesis and impaired nitrogen use during infusion of a synthetic amino acid formula. NEJM. 1982;306:1013.

<!--[if !supportFootnotes]--> [4]<!--[endif]--> Unno N, Fink MP. Intestinal epithelial hyperpermeability: mechanisms and relevance to disease. Gastroenterol Clin. 1998;27(2):289-307.

<!--[if !supportFootnotes]--> [5]<!--[endif]--> Bjarnason I, MacPherson A, Hollander D. Intestinal permeability: an overview. Gastroenterol. 1995;108:1566-81.

<!--[if !supportFootnotes]--> [6]<!--[endif]--> Wyatt J, Oberhuber G, Pangratz S, et al. Increased gastric and intestinal permeability in patients with Crohn’s disease. Am J Gastroenterol. 1997;92(10):1891-6.

<!--[if !supportFootnotes]--> [7]<!--[endif]--> CDC guidelines for preventing opportunistic infections among HIV-infected persons-2002 recommendations of the Infectious Diseases Society of America. MMWR. 2002;51(RR-8):1-2.

<!--[if !supportFootnotes]--> [8]<!--[endif]--> Echeverria PS, Jonnalagadda SS, Hopkins BL, Rosenbloom CA. Perception of quality of life of persons with HIV/AIDS and maintenance of nutritional parameters while on protease inhibitors. AIDS Patient Care STDS. 1999;13(7):427-33.

<!--[if !supportFootnotes]--> [9]<!--[endif]--> Volberding PA, Sande M, Deeks SG. The Medical Management of AIDS. Phila:WB Saunders;1999:97-201.

<!--[if !supportFootnotes]--> [10]<!--[endif]--> Mooney M, Vergel N. Built to Survive. Los Angeles:PoWeR;1999:111-26.

<!--[if !supportFootnotes]--> [11]<!--[endif]--> Kaminski M, Weil S, Bland J, Jan P. AIDS wasting syndrome as an entero-metabolic disorder: the gut hypothesis. Alt Med Rev. 1998;3(1):40-53.

<!--[if !supportFootnotes]--> [12]<!--[endif]--> Oktedalen O, Skar V, Dahl E, Serck-Hanssen A. Changes in small intestinal structure and function in HIV-infected patients with chronic diarrhoea. Scand J Infect Dis. 1998;30(5):459-63.

<!--[if !supportFootnotes]--> [13]<!--[endif]--> Woodcock A, Bradley C. Validation of the HIV treatment satisfaction questionnaire. Qual Life Res. 2001;10(6):517.
 

Articles, Reports & PNI Press Releases

Improvement in mucosal integrity and function...

IMPROVEMENT IN MUCOSAL INTEGRITY AND FUNCTION IN IBD PATIENTS AND REDUCTION IN GI SYMPTOMS IN HIV PATIENTS WITH DIETARY PEPTIDES FROM HYDROLYZED WHITE FISH

Nichols TW, DelRossi J

Center for Nutrition and Digestive Disorders, Hanover, PA, USA

ABSTRACT (Regulatory Peptides. 2002;108(1):31)

Dietary peptides are known to have biological importance beyond their nutritive value as protein, influencing structural, immune, and gastrointestinal functions.  The GI benefit of supplementation with a dietary bioactive peptide supplement prepared from hydrolyzed white fish was studied in two distinct populations in separate trials.  In the first study, 15 IBD patients assessed to have gut mucosal hyperpermeability by a urine test utilizing lactose and mannitol ratios were given either 3g per day of the fish peptide supplement or a control for 6 weeks, followed by a second permeability test and symptom assessment scoring.  Results with the IBD patients taking the supplement showed a trend towards improvement in both intestinal permeability and symptom assessment versus controls.  We then hypothesized that if GI symptoms resulting from current recommended HIV therapy are associated with a similar inflammatory mechanism, these patients would also respond favorably to the peptide supplementation.  Accordingly, a second population of 23 HIV-infected males experiencing GI side effects on highly active antiretroviral therapy (HAART) were given either 3g per day of the fish peptide supplement or a control for 5 months, with symptoms assessed before and after the treatment period.  In the HIV patients, the number of GI symptoms collectively reported as decreased in the supplement group was significantly greater than the number of symptoms collectively reported as decreased in the control group.  These bioactive peptides appear to have a dual function in HIV patients: controlling intestinal permeability as a potential long-term risk factor of HAART and reducing the GI side effects of HAART, which may relate to increased compliance and improved treatment outcome.

Read More

Preliminary reports: Improvement in mucosal integrity in IBD patients and reduction in GI symptoms..

Preliminary reports: Improvement in mucosal integrity in IBD patients and reduction in GI symptoms in HIV patients with hydrolyzed white fish, by Trent W Nichols MD, Paul D Thomas DO, John DelRossi MPAS, PA-C, Angie Angstadt BS, and Barry W Ritz BS (Integrative Medicine 2003)

 

Click here for pdf.

Read More

Proper Nutrition History

PROPER NUTRITION INCORPORATED

Founded in 1994 by Dr. Donald Snyder and headquartered in Reading, Pa., Proper Nutrition, Inc. is built on a record of innovation stretching back to the early 1960s, when Dr. Snyder, as the head of a U.S. Department of the Interior Fisheries Research Laboratory, led the charge against world hunger. At that time, protein deficiency was determined to be the most common and serious aspect of world hunger. Alarmed by starvation and malnutrition among third world nations, particularly among children and infants, many nations joined forces to launch a major worldwide humanitarian project to find an inexpensive source of protein to solve this problem. Dr. Snyder, as a member of a special committee of the U.S. National Academy of Sciences, was instrumental in developing an economically feasible method of providing protein to the world’s hungry.

A breakthrough came in the form of revolutionary FPC (Fish Protein Concentrate) technology, which allowed quality protein, retaining all of its original nutritional value, to be delivered to the body in a highly absorbable form. FPC was made available to the World Health Organization of the United Nations to aid in famine relief. Only after years of further testing and research were the additional healing benefits of this blending of science and nature discovered.

Today, Dr. Snyder and Proper Nutrition, Inc. offer revolutionary dietary supplements, including Intestive®, available directly to consumers; and SEACURE® and SEAVIVE®, professional products available for distribution by healthcare practitioners and retailers. Proper Nutrition’s current line of high quality nutritional supplements is the direct result of 40 years of research and refinement aimed at perfecting the FPC technology that was conducted by a highly skilled team of scientific experts. Derived from deep-ocean white fish, Proper Nutrition supplements offer proven alternatives for the support of the gastrointestinal tract and the promotion of immune system health. Further development and research is ongoing to extend the benefits of FPC technology to wound-healing and chemotherapy support supplements.

Intestive®, the first of Proper Nutrition’s consumer products, is specially formulated with all-natural ingredients to promote complete gastrointestinal health. Intestive® is a safe, effective and drug-free alternative for mitigating the symptoms commonly associated with Irritable Bowel Syndrome (IBS). IBS symptoms involve chronic or recurrent abdominal pain, the sudden and urgent need to go to the bathroom, bloating, and frequent diarrhea or constipation. The number of people in the U.S. suffering from IBS has been estimated to be as high as one in five.

For additional questions or consumer information please call (800) 555-8868 Monday-Friday, 9AM-5PM EST or visit www.propernutrition.com. To place an order by phone 24 hours/day, please call (800) 247-5656 or visit www.propernutrtion.com.

Read More

Proper Nutrition Announces the Launch of Intestive® – Support for Intestinal/Bowel Discomfort

READING, PA. — Proper Nutrition, Inc. this week announced the release of Intestive®, a new clinically tested, side effect-free, all-natural treatment for Irritable Bowel Syndrome (IBS), a chronic disorder affecting millions of Americans. Intestive® contains Seacure®, a fish protein concentrate originally developed by scientists 40 years ago for use by the World Health Organization to fight famine-related gastrointestinal problems around the world.

IBS affects at least one out of five people in the United States1, and afflicts three times as many women as men2. Symptoms involve chronic or recurrent abdominal pain, the sudden and urgent need to go to the bathroom, frequent diarrhea or constipation, and bloating. IBS is an ongoing problem, and while it is not fatal, the chronic discomfort and acute embarrassment of IBS hamper the lives of millions of Americans every day, hindering social outings, regular work schedules, and family time. IBS is also known as spastic colon, spastic bowel, functional bowel disease, and nervous stomach. While there is no cure for IBS, recent developments in the management of IBS symptoms promise a greatly improved quality of life for IBS sufferers.

Intestive® is the latest breakthrough in the management of IBS. Intestive® gives IBS sufferers a chance to take control of their lives again by effectively alleviating IBS symptoms, safely and comprehensively. In addition to relieving chronic diarrhea and constipation, Intestive® also fosters a healthy intestinal lining and improves overall bowel function dramatically. While proteins are essential to a healthy diet, complex proteins are often difficult to absorb. Because Intestive® contains high-levels of bio-active peptides and amino acids — proteins in their simplest forms — it is easily absorbed by the body. Intestive® helps to maintain the body’s delicate balance and regulate gastrointestinal health at a cellular level by supplying proteins that have been broken into their basic building blocks, yet retain all of their nutritional value.

Intestive® is the effective all-natural alternative to prescription or over-the-counter remedies, which often alleviate only some of the symptoms experienced by IBS sufferers. Moreover, Intestive® produces none of the side effects — such as constipation and intestinal pain — sometimes associated with other treatments for gastrointestinal problems.

In addition to the concentrated bio-active peptides and amino acids that make Intestive® so effective, this new supplement also supplies boswellia, a natural anti-inflammatory; colostrum, free of caseine and lactose, to fight infection; and omega-3 fatty acids.
"Americans eat plenty of protein, but it isn’t always the right kind to maintain a healthy internal balance. For years, we’ve known that eating fish may help us to resist colitis, arthritis, heart disease and a host of other health problems," explains Dr. Donald Snyder. "Essential fatty acids and other important nutritional requirements are found in fish, in a form that our bodies can easily absorb. Intestive® helps a body suffering from IBS to achieve a healthy balance and maintain it."

Intestive® is currently available only through the Proper Nutrition Web site at www.propernutrition.com or by phone at (800) 247-5656. Based on clinical studies, Proper Nutrition has launched a program to develop the applications of the Seacure® concentrate used in Intestive®, extending its benefits to other health issues. For more information on Intestive® or Proper Nutrition, call (800) 555-8868 or visit www.propernutrition.com.

1. Irritable Bowel Syndrome & The Mind-Body/Brain-Gut Connection, William B. Salt II, MD; Parkview Publishing, 1998.
2. Knight Ridder Newspapers, 2000.

Read More

Worry-free IBS Support Now Available With Intestive®

With public concern mounting about side effects from treatments for Irritable Bowel Syndrome (IBS), many IBS sufferers are turning to all-natural, drug-free remedies, like new Intestive® from Proper Nutrition, Inc., for the support of gastrointestinal health. Intestive® is a breakthrough in promoting healthy gastrointestinal and bowel function, without inconvenient or uncomfortable side effects. Intestive® is the effective all-natural alternative to prescription or over-the-counter remedies.

In fact, the primary ingredient in Intestive®, SEACURE®, a 100% white fish protein concentrate, has a long history of safe and effective use. Developed by scientists 40 years ago, for use in fighting worldwide famine, SEACURE® has resulted in no reported cases of side effects or adverse reactions, even among infants. A recently published initial study demonstrates the protein concentrate’s effectiveness in reducing IBS symptoms. Furthermore, the two additional active ingredients in Intestive®, colostrum (free of casein and lactose) and boswellia, are all-natural products known to be safe and effective.

Intestive® is currently available only through the Proper Nutrition Web site at www.propernutrition.com or by phone at (800) 247-5656. For more information on Intestive® or Proper Nutrition, call (800) 555-8868 or visit www.propernutrition.com.

Read More

IBS Treatment Without Dangerous Side Effects

In an election year, when big pharmaceutical companies are lining the pockets of legislators, the health of Americans may be in jeopardy. According to an article in The Wall Street Journal this week, "The Food and Drug Administration is reviewing a handful of deaths and several dozen unusual side effects in patients who had taken [a pharmaceutical drug] to treat irritable bowel syndrome."

A difficult and embarrassing affliction to discuss with friends or even healthcare professionals, Irritable Bowel Syndrome (IBS) affects nearly 20 percent of the population – more than 55 million Americans. Although IBS does not have big-name star power pushing for a solution – as Katie Couric does for colon cancer, Michael J. Fox does for Parkinson’s Disease or Rosie O’Donnell does for breast cancer – it is an urgent issue for one out of five Americans.

The good news is that IBS sufferers now have a safe, effective alternative to pharmaceutical drugs. An all-natural, drug-free remedy, Intestive® from Proper Nutrition, Inc., is a breakthrough in promoting gastrointestinal health and bowel function, without the inconvenient, uncomfortable or life-threatening side effects. In fact, the primary ingredient in Intestive®, SEACURE®, a 100% white fish protein concentrate, has been used safely and effectively for more than 40 years. Developed by scientists for use in fighting worldwide famine, SEACURE® has resulted in no reported cases of side effects or adverse reactions, even among infants. And, a recently published initial study demonstrates that the new SEACURE®-based product Intestive® was effective in improving general health in just under 85% of patients in as little as 30 days. Furthermore, the two additional active ingredients in Intestive®, colostrum (free of casein and lactose) and boswellia, are all-natural products known to be safe.

Intestive® is currently available only through the Proper Nutrition Web site at www.propernutrition.com or by phone at (800) 247-5656. For more information on Intestive® or Proper Nutrition, call (800) 555-8868 or visit www.propernutrition.com.

Read More

IBS Sufferers Reliant on Withdrawn Pharmaceutical Treatment Can Turn to All-Natural Solution

SAFE, EFFECTIVE ALTERNATIVE TO PRESCRIPTION IBS DRUG

IBS Sufferers Reliant on Withdrawn Pharmaceutical Treatment Can Turn to All-Natural Solution

This week, pharmaceutical giant Glaxo Wellcome, Inc. announced the withdrawal of Lotronex, a pharmaceutical drug for the treatment of Irritable Bowel Syndrome (IBS), bringing to the forefront this disorder that affects as many as 55 million American adults yet is virtually unknown to the public. According to the International Foundation for Functional Gastrointestinal Disorders (IFFGD), IBS is the second leading cause of illness-related absenteeism from work or school (second only to the common cold) and the most common disease diagnosed by gastroenterologists. Physicians cite IBS as one of the top 10 most frequent diagnoses nationally, yet this widespread gastrointestinal disorder remains a hidden malady.

A difficult and embarrassing affliction to discuss with friends or even healthcare professionals, Irritable Bowel Syndrome (IBS) affects approximately 15-20 percent of the American population. Although IBS does not have big-name star power pushing for a solution – as Katie Couric does for colon cancer, Michael J. Fox does for Parkinson’s Disease or Rosie O’Donnell does for breast cancer – it is an urgent issue for one out of five Americans. With the withdrawal from market of the controversial pharmaceutical IBS treatment, sufferers must now look elsewhere to maintain their health and quality of life, an especially critical issue during this holiday season. While the exact causes of IBS have yet to be determined, holiday stress and rich holiday foods are sure to be IBS triggers for many.

The good news is that IBS sufferers now have a safe, effective alternative to pharmaceutical drugs. An all-natural, drug-free remedy, Intestive® from Proper Nutrition, Inc. is a breakthrough in promoting gastrointestinal health and bowel function, without the inconvenient, uncomfortable or life-threatening side effects. In fact, the primary ingredient in Intestive®, SEACURE®, a 100 percent white fish protein concentrate, has been used safely and effectively for more than 40 years. Developed by scientists for use in fighting worldwide famine, SEACURE® has resulted in no reported cases of side effects or adverse reactions, even among infants. And, a recently published initial study demonstrates that the new SEACURE®-based product Intestive® was effective in improving general health in just under 85 percent of patients in as little as 30 days. Furthermore, the two additional active ingredients in Intestive®, colostrum (free of casein and lactose) and boswellia, are all-natural products known to be safe.

Intestive® is currently available only through the Proper Nutrition Web site at www.propernutrition.com or by phone at (800) 247-5656. For more information on Intestive or Proper Nutrition, or to arrange an interview with a Proper Nutrition spokesperson, please contact (800) 555-8868 or visit www.propernutrition.com.

Read More

Colostrum 80/40™: Specially Prepared to Remove the Casein and Lactose

Reading, PA – Proper Nutrition, Inc., has announced the release of Colostrum 80/40™, a hyperimmune bovine colostrum product concentrated through advanced fermentation and ultrafiltration techniques to deliver the highest immunoglobulin G (IgG) content available on the market, without the casein and lactose.

IgG is an antibacterial, antitoxic, and antiviral protein, and is the principal immune factor naturally present in colostrum. Proper Nutrition’s Colostrum 80/40™ is concentrated through the removal of fat, casein, and and lactose to contain a minimum of 80% protein and 40% IgG by total dry weight. Many colostrum producers claim 40% IgG, meaning that 40% of the protein is in the form of IgG, which can translate into as little as 20% of the total colostrum in each capsule. Colostrum 80/40™ provides 40% IgG by total dry weight.

Proper Nutrition’s Colostrum 80/40™ is specially prepared to remove the casein and lactose normally present in whole colostrum and tested to confirm that the final product contains less than 1% casein and less than 1% lactose by dry weight. Finally! Colostrum 80/40™ delivers the immune-supportive benefits of colostrum to the hundreds of thousands of people who need to avoid casein and/or lactose as a result of food intolerances and allergies.

Proper Nutrition is your source for colostrum products of U.S. origin, and Colostrum 80/40™ is your answer to high quality colostrum without the casein and lactose. Proper Nutrition colostrum products are available to health care professionals and retailers at 800-735-2051. For more information, visit www.propernutrition.com or call Proper Nutrition at 800-555-8868. Product photos available.

Read More

North America's Largest Supplier of Colostrum—It's Not Who You Think

NORTH AMERICA’S LARGEST SUPPLIER OF COLOSTRUM—IT’S NOT WHO YOU THINK

Reading, PA – Proper Nutrition, Inc., maker of Seacure® hydrolyzed white fish dietary supplement, has unveiled a line of high-quality colostrum products in cooperation with La Belle, Inc., North America’s largest supplier of colostrum.

The bovine colostrum is from dairy herds of U.S. origin only, fed diets free of animal by-products, as well as free of antibiotics, hormones, and pesticides. Proper Nutrition does not use colostrum from European or New Zealand sources. Proper Nutrition’s colostrum is produced in state-of-the-art, licensed food processing facilities in Washington and California. These facilities follow GMP procedures and are USDA inspected.

Proper Nutrition has introduced Colostrum 80/40™, the only colostrum product on the market specially prepared to remove the fat, casein, and lactose. Colostrum 80/40™ provides the highest level of immunoglobulin G (IgG) available in any colostrum product.

Read More

In Memorium: Donald G. Snyder, PhD

or Immediate Release                                               January 3, 2003


Contact:           Barry W. Ritz  800-555-8868 barry@propernutrition.com


In Memorium: Donald G. Snyder, PhD


Reading, PA- Proper Nutrition, Inc., regrets to announce that Dr. Donald Snyder passed away on December 25 at the age of 76.  “Doc” Snyder founded Proper Nutrition, Inc., in 1994, and served as the company’s CEO.


Doc received his PhD in biochemistry and nutrition from Georgetown in 1957.  His career included various positions as a government employee until 1969 and as an independent consultant from 1969-1994.  He served as Director of the Fisheries Technological Laboratory of the Department of the Interior and was involved with such organizations as the Food and Nutrition Board of the United Nations, the National Academy of Sciences, and the National Research Council.  He played an integral role in the development of fish protein concentrate to combat world malnutrition and established Proper Nutrition, Inc., in 1994, to market one such fish protein concentrate as Seacure® for its clinical applications.


Doc was a World War II veteran and enjoyed playing the trumpet in his Big Band.  He had an unceasing sense of humor and a knack for telling stories and jokes.  He will be greatly missed, although his contributions to nutrition science remain ever present.

Read More

Seacure® for pets

Reading, PA—Proper Nutrition, Inc., announces that its specialty dietary supplement Seacure® used to support intestinal health and healing will be available to veterinarians and pet owners under a pet label on August 1, 2003.


This new packaging comes in response to overwhelming satisfaction from consumers and holistic vets who have been sharing the human dietary supplement with their pets.  Seacure®  for pets complies with product labeling regulations for pet supplementation, including clear dosing instructions for animals.


Seacure® hydrolyzed white fish has been used successfully as a human dietary supplement for over 40 years, with its roots in efforts to quench world malnutrition led by the late Dr. Donald Snyder.  A high-quality protein supplement, Seacure® supports digestion and healthy skin & coat in animals.  Dogs and cats enjoy the white fish flavor.


Electronic photo available upon request.

Read More

Follow us in these Social Networks: